915037-55-7

Basic information

• Product Name: N-methyl-4-(5-nitro-1H-indol-3-yl)cyclohex-3-enamine
• Synonyms: N-methyl-4-(5-nitro-1H-indol-3-yl)cyclohex-3-enamine
• CAS NO: 915037-55-7
• Molecular Weight: 271.319
• Mol File: 915037-55-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-methyl-4-(5-nitro-1H-indol-3-yl)cyclohex-3-enamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-4-(5-nitro-1H-indol-3-yl)cyclohex-3-enamine(915037-55-7)
• EPA Substance Registry System: N-methyl-4-(5-nitro-1H-indol-3-yl)cyclohex-3-enamine(915037-55-7)

Safety Data

• Hazardous Substances Data: 915037-55-7(Hazardous Substances Data)

Upstream product

• 6146-52-7 5-nitroindole 
• 915037-53-5 5-nitro-3-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1H-indole 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 915037-54-6 4-(5-nitro-1H-indol-3-yl)cyclohex-3-enone 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 915036-67-8 N-(3-(4-(methylamino)cyclohex-1-enyl)-1H-indol-5-yl)thiophene-2-carboximidamide 
• 915037-57-9 tert-butyl 4-(5-amino-1H-indol-3-yl)cyclohex-3-enyl(methyl)carbamate 
• 1152478-37-9 (S)-N-(3-(4-(methylamino)cyclohex-1-enyl)-1H-indol-5-yl)thiophene-2-carboximidamide 
• 1152478-39-1 (R)-N-(3-(4-(methylamino)cyclohex-1-enyl)-1H-indol-5-yl)thiophene-2-carboximidamide 
• 915037-56-8 tert-butyl methyl(4-(5-nitro-1H-indol-3-yl)cyclohex-3-enyl)carbamate 

Relevant articles and documents

First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain

A family of different 3,5-disubstituted indole derivatives having 6-membered rings were designed, synthesized, and demonstrated inhibition of human nitric oxide synthase (NOS) with norepinephrine reuptake inhibitory activity (NERI). The structure-activity

Substituted indole compounds having NOS inhibitory activity

The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination w